Position

Academic Status
Flinders Centre for Innovation in Cancer

Qualifications

MBBS
FRACP

Teaching interests

Optimal use of anti-cancer drugs, familial cancers, supportive care in cancer

Research expertise

  • Oncology and carcinogenesis

Research interests

Anti-cancer therapeutics
Neuro oncology
Gynaecological cancers
Genitourinary cancers
Rare cancers - cancer of unknown primary, endocrine cancers and others
Supportive care

Publications

  • Klevansky, M., Mislang, A., Kwatra, V., Griffiths, C., Hsieh, A., Ullah, S., et al. (2015). FOLFIRINOX for advanced pancreato-biliary adenocarcinoma, a multi-centre retrospective analysis: The South Australian Experience. In ESMO Asia Congress. ESMO Asia Congress. Singapore.
  • Van Dyk, M., Miners, J., Kichenadasse, G., McKinnon, R. and Rowland, A. (2015). A Novel UPLC-MS Approach For The Quantification Of 13 Clinically Used Kinase Inhibitors. In Proceedings of the Joint ASCEPT-BPS Scientific Meeting. Joint ASCEPT-BPS Scientific Meeting. Hong Kong. May 2015.
  • Sorich, M., Rowland, A., Dias, M.M., McKinnon, R.A., Kichenadasse, G., Wiese, M., et al. (2015). BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis. In Journal of Clinical Oncology. Alexandria, VA: American Society of Oncology. American Society of Clinical Oncology. Chicago. May 2015, pp. e14605.
  • Lawn, S., Zrim, S., Leggett, S., Miller, M., Jones, L., Dollman, J., et al. (2013). Utility of a self-management approach in lifestyle interventions for cancer survivors - preliminary findings from the NAPA trial. ASBHM. Australasian Society for Behavioural Health and Medicine Newcastle February 2013. Newcastle, NSW Australia. Feb 2013.
    [Web Link]
  • Lee, J., Padman, S., kumar, R., Slee, M., Richards, A., Koczwara, B., et al. (2013). Late effects of ozaliplatin-induced peripheral neuropathy (LEON) In Asia-Pacific Journal of Clinical Oncology. Abstract 179 ed. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age. Adelaide, Australia. Nov 2013, pp. 112-112.
  • Loukas, B., Padman, S., Roy, A., Koczwara, B., Kichenadasse, G., Sukumaran, S., et al. (2013). Monitoring and Treatment of Hypomagnesaemia in Patients Receiving Cetuximab. In Asia-Pacific Journal of Clinical Oncology. Abstract 181 ed. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age. Adelaide, Australia. Nov 2013, pp. 112-112.
  • Miller, J., Martin, H., Young, F., Khattak, M., Kichenadasse, G., Sukumaran, S., et al. (2013). A prospective study of anti-mullerian hormone (AMH) as a potential predictor of chemotherapy-induced menopause: preliminary results. In Asia-Pacific Journal of Clinical Oncology. Abstract 183 ed. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age. Adelaide, Australia. Nov 2013, pp. 113-113.
  • Padman, S., Lee, J., kumar, R., Slee, M., Richards, A., Koczwara, B., et al. (2013). Qualitative Results of the LEON study: late effects of oxaliplatin-induced peripheral neuropathy. In Asia-Pacific Journal of Clinical Oncology. Abstract 191 ed. COSA's 40th Annual Scientific Meeting. Cancer Care Coming of Age. Adelaide, Australia. Nov 2013, pp. 115-116.
  • Takhar, H., Sukumaran, S., Ly, M., Karapetis, C., Roy, A., Kichenadasse, G., et al. (2013). Impact of age on treatment and survival in patients with small cell lung cancer. In Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO) Annual Meeting, pp. Abstract e20577.
  • Takhar, H., Sukumaran, S., Ly, M., Woodman, R., Karapetis, C., Koczwara, B., et al. (2013). Impact of pre-treatment serum lactate dehydrogenase on survival in patients. In Journal of Thoracic Oncology. 15th World Conference on Lung Cancer. Sydney, Australia. Oct 2013, pp. P1.13-003.
  • Zrim, S., Miller, M., Lawn, S., Leggett, S., Jones, L., Karapetis, C., et al. (2013). A pilot study of tailored nutrition and physical activity intervention in cancer survivors. In Asia-Pacific Journal of Clinical Oncology. Abstract 280 ed. Cancer Care Coming of Age, Clinical Oncology Society of Australia (COSA), Annual Scientific Meeting (ASM) Nov 2013, pp. 139-140.
  • Zrim, S., Miller, M., Lawn, S., Leggett, S., Jones, L., Karapetis, C., et al. (2013). A pilot study of tailored nutrition and physical activity intervention in cancer survivors. COSA. Clinical Oncology Society of Australia ASM. Adelaide South Australia. Nov 2013.
    [Web Link]
  • Kichenadasse, G., Rowland, A. and Miners, J. (2012). Inhibition of human UDP-Glucuronosyltransferase 1A (UGT1A) enzymes by three different Tyrosine Kinase Inhibitors (Lapatinib, Pazopanib and Sorafenib): implications for drug interactions and jaundice. In Proceedings of the 46th Annual ASCEPT Annual Scientific Meeting. Sydney, Australia: ASPECT. 46th ASCEPT Annual Scientific Meeting. Sydney, Australia. Dec 2012.
  • Miners, J., Kichenadasse, G. and Rowland, A. (2012). Assessment of sorafenib inhibition of UDP-Glucuronosyltransferase; Implications for onset of jaundice in Gilbert patients. In Proceedings of the North American Regional ISSX Meeting. Dallas, Texas: North American ISSX. North American Regional ISSX Meeting. Dallas, Texas. Oct 2012.
  • Roy, A., Ting, K., Selva-Nayagam, S., Singhal, N., Kichenadasse, G., Jain, K., et al. (2010). Toxicity and Patient Tolerance of Oxaliplatin based treatment for colorectal cancer (FOLFOX) - A retrospective audit of patterns of care in two major cancer centres in Adelaide. In Asia-Pacific Journal of Clinical Oncology. Medical Oncology Group of Australia (MOGA) Anuual Scientific Meeting, pp. Abstract 16.
    [Web Link]
  • Bishnoi, S., Iyngkaran, T., Au, V., Roy, A., Bowden, J., Koczwara, B., et al. (2009). Diagnosis of BAC and ABAC in clinical practice- Are we doing it right? In Asia-Pacific Journal of Clinical Oncology. Clinical Oncology Society of Australia (COSA) Conference. Gold Coast, Queensland, Australia, pp. Abstract 207.
  • Tran, L.K., Kichenadasse, G., Ormsby, R.J., Morel, K.L., Butler, L.M., Centenera, M., et al. (2017). MP83-08 combination of metformin and sodium valproate for prostate cancer: a rapid approach from bench to clinical trial. Journal of Urology, 197(4) pp. 1108-1109.
    [10.1016/j.juro.2017.02.2576]
  • Mangoni, A.A., Woodman, R.J., Kichenadasse, G., Rowland, A. and Sorich, M. (2016). Anti-VEGF-induced hypertension and cancer outcomes: translating research into clinical practice. Expert Review of Precision Medicine and Drug Development, 1(2) pp. 12 5-127.
    [10.1080/23808993.2016.1155963] [10.1080/23808993.2016.1155963]
  • Kumar, R., Patel, G.S., Kichenadasse, G., Sukumaran, S., Roy, A., Koczwara, B., et al. (2015). Delayed onset of benign pleural effusion following concurrent chemoradiotherapy for inoperable non-small-cell lung cancer. Internal Medicine Journal, 45(2) pp. 218-221.
    [10.1111/imj.12658]
  • O'Callaghan, M., Kichenadasse, G. and Moretti, K.L. (2015). Informed decision making about prostate cancer screening. Annals of Internal Medicine, 162(6) pp. 457.
    [Scopus] [Web Link] [Web Link]
  • Rowland, A., Dias, M.M., Wiese, M.D., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S., et al. (2015). Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’ British Journal of Cancer,
    [10.1038/bjc.2015.325] [Scopus]
  • Kichenadasse, G. and Karapetis, C. (2013). Abiraterone in metastatic prostate cancer. New England Journal of Medicine, 368(15) pp. 1457-1459.
    [10.1056/NEJMc1301594] [Scopus]
  • Khattak, M., Martin, H., Martin, J., Hollington, P. and Kichenadasse, G. (2012). Capsule endoscopy related small bowel obstruction in a patient with radiation enteritis. International Journal of Medicine and Medical Sciences, 2(2) pp. 63-64.
    [Web Link] [Web Link]
  • Kichenadasse, G., Sukumaran, S. and Karapetis, C. (2011). Early stage ovarian cancers: Angiogenesis inhibition and clear cell cancers. Gynecologic Oncology, 123(2) pp. 426.
    [10.1016/j.ygyno.2011.07.036] [Scopus]
  • Kichenadasse, G., Townsend, A. and Price, T.J. (2008). Rectal cancer in the elderly- lessons learned. Cancer Forum, 32(1) pp. 20-22.
    [Scopus] [Web Link] [Web Link]
  • Gupta, A., Sharma, M.C., Kochupillai, V., Kichenadasse, G., Gupta, A., Atri, S., et al. (2007). Primary Pulmonary Rhabdomyosarcoma in Adults: Case Report and Review of Literature. Clinical Lung Cancer, 8(6) pp. 389-391.
    [Scopus] [Web Link]
  • Kichenadasse, G., Goel, R., Kumar, K. and Bakhshi, S. (2007). Biphenotypic extramedullary blast crisis as a presenting manifestation of Philadelphia chromosome-positive CML in a child. Pediatric Hematology and Oncology, 24(3) pp. 195-198.
    [10.1080/08880010701198787] [Scopus]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Wiese, M.D., et al. (2017). Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing interindividual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology, 13(1) pp. 31-49.
    [10.1080/17425255.2016.1229303] [Scopus]
  • Miners, J.O., Chau, N., Rowland, A., Burns, K.W., McKinnon, R.A., Mackenzie, P.I., et al. (2017). Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubunemia. Biochemical Pharmacology, 129 pp. 85-95.
    [10.1016/j.bcp.2017.01.002]
  • Miller, M.D., Zrim, S.A., Lawn, S.J., Woodman, R.J., Leggett, S.M., Jones, L., et al. (2016). A pilot study of self-management-based nutrition and physical activity intervention in cancer survivors. Nutrition and Cancer-An International Journal,
    [10.1080/01635581.2016.1170169] [10.1080/01635581.2016.1170169]
  • Van Dyk, M., Miners, J.O., Kichenadasse, G., McKinnon, R.A. and Rowland, A. (2016). A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: a novel platform for optimised KI dosing. Journal of Chromatography B-Analytical Technologies in The Biomedical and Life Sciences, 1033-1034 pp. 17-26.
    [10.1016/j.jchromb.2016.07.046] [10.1016/j.jchromb.2016.07.046] [Scopus]
  • Rowland, A., Karapetis, C.S., Mangoni, A.A., Wiese, M., Kichenadasse, G., McKinnon, R.A., et al. (2016). Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Translational Cancer Research, 5(Suppl 1) pp. S31-S34.
    [10.21037/tcr.2016.05.19] [10.21037/tcr.2016.05.19]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Weise, M.D., et al. (2016). Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology,
    [10.1080/17425255.2016.1229303] [10.1080/17425255.2016.1229303]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Wiese, M., et al. (2016). Kinase inhibitor pharmacokinetics: Comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology,
    [10.1080/17425255.2016.1229303] [10.1080/17425255.2016.1229303]
  • Sorich, M., Kichenadasse, G., Rowland, A., Woodman, R.J. and Mangoni, A.A. (2016). Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF targeted therapy: A pooled secondary analysis of clinical trials. International Journal of Cancer, 138 pp. 2293-2299.
    [10.1002/ijc.29972] [Scopus]
  • Sorich, M., Rowland, A., Kichenadasse, G., Woodman, R.J. and Mangoni, A.A. (2016). Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. British Journal of Cancer, 114(12) pp. 1313-1317.
    [10.1038/bjc.2016.147] [Scopus]
  • Kichenadasse, G., Sweet, L.P., Harrington, A.C. and Ullah, S. (2016). The current practice, preparedness and educational preparation of oncology professionals to provide spiritual care. Asia-Pacific Journal of Clinical Oncology,
    [10.1111/ajco.12654] [10.1111/ajco.12654]
  • Khasraw, M., Lee, A., McCowatt, S., Kerestes, Z., Buyse, M.E., Back, M., et al. (2016). Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. JOURNAL OF NEURO-ONCOLOGY,
    [10.1007/s11060-016-2094-0] [Scopus] [Scopus]
  • Rowland, A., Dias, M.M., Wiese, M., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S., et al. (2016). Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. European Journal of Cancer, 55(3) pp. 122-130.
    [Scopus] [Scopus]
  • Padman, S., Lee, J., kumar, R., Slee, M., Hakendorf, P.H., Richards, A., et al. (2015). Late effects of oxaliplatin-induced peripheral neuropathy (LEON)—cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years. Supportive Care in Cancer,
    [10.1007/s00520-014-2423-9]
  • Davis, I.D., Long, A., Yip, S., Espinoza, D., Thompson, J.F., Kichenadasse, G., et al. (2015). EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6) pp. 1118-1123.
    [10.1093/annonc/mdv078] [Scopus]
  • Rowland, A., Dias, M.M., Wiese, M.D., Kichenadasse, G., McKinnon, R.A., Karapetis, C.S., et al. (2015). Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British Journal of Cancer, 112(12) pp. 1888-1894.
    [10.1038/bjc.2015.173] [Scopus]
  • Sorich, M., Wiese, M., Rowland, A., Kichenadasse, G., McKinnon, R.A. and Karapetis, C. (2015). Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Annals of Oncology, 26(1) pp. 13-21.
    [10.1093/annonc/mdu378] [Scopus] [PubMed] [Web Link]
  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., et al. (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) Annals of Oncology, 25(1) pp. 143-148.
    [10.1093/annonc/mdt369] [Scopus]
  • Hocking, C. and Kichenadasse, G. (2014). Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Supportive Care in Cancer, 22(4) pp. 1143-1151.
    [Scopus] [Scopus]
  • Knott, V., Zrim, S.A., Shanahan, E.M., Anastassiadis, P.L., Lawn, S., Kichenadasse, G., et al. (2014). Returning to work following curative chemotherapy: a qualitative study of return to work barriers and preferences for intervention. Supportive Care in Cancer, 22(12) pp. 3263-3273.
    [10.1007/s00520-014-2324-y]
  • Lawn, S., Zrim, S., Leggett, S., Miller, M., Woodman, R., Jones, L., et al. (2014). Is self-management feasible and acceptable for addressing nutrition and physical activity needs of cancer survivors? Health Expectations, 18(6) pp. 3358-3373.
    [10.1111/hex.12327] [Scopus]
  • Patel, G., Jain, K., Kumar, R., Strickland, A., Pellegrini, L., Slavotinek, J., et al. (2014). Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Supportive Care in Cancer, 22(1) pp. 121-128.
    [10.1007/s00520-013-1941-1] [Scopus]
  • Reed, N., Gomez-Garcia, E., Gallardo-Rincon, D., Barrette, B., Baumann, K., Friedlander, M., et al. (2014). Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24(S3) pp. S35-S41.
    [Scopus]
  • Reed, N.S., Pautier, P., Avall-Lundqvist, E., Choi, C.H., du Bois, A., Friedlander, M., et al. (2014). Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian small cell cancers. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 24(S3) pp. S30-S33.
    [Scopus]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Blomfield, P., Grant, P., et al. (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4) pp. 359-366.
    [10.3802/jgo.2013.24.4.359] [Scopus]
  • Olver, I., Grimison, P., Chatfield, M., Stockler, M., Toner, G., Gebski, V., et al. (2013). Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Supportive Care in Cancer, 21(6) pp. 1561-1568.
    [10.1007/s00520-012-1696-0] [Scopus]
  • Shaikh, M., Kichenadasse, G., Choudhury, N., Butler, R. and Garg, S. (2013). Non-vascular drug eluting stents as localized controlled drug delivery platform: Preclinical and clinical experience. Journal of Controlled Release, 172(1) pp. 105-117.
    [10.1016/j.jconrel.2013.08.010] [Scopus]
  • Hodgson, K., Wilson, C., Hutchinson, A., Nettelbeck, T., Kichenadasse, G. and Zajac, I. (2012). The Effect of Chemotherapy on Cognition in Patients treated for Colorectal Cancer. Advances in Cancer Research & Treatment, 2012(906659)
    [10.5171/2013.906659]
  • Hutchinson, A., Hosking, J.R., Kichenadasse, G., Mattiske, J. and Wilson, C. (2012). Objective and subjective cognitive impairment following chemotherapy for cancer: A systematic review. Cancer Treatment Reviews, 38(7) pp. 926-934.
    [10.1016/j.ctrv.2012.05.002] [Scopus]
  • Roy, A.C., Jones, D., Slavotinek, J., Kichenadasse, G., Karapetis, C., Lam, E., et al. (2011). Very high GFR in cancer patients undergoing chemotherapy: prevalence, carboplatin dosing patterns and chemotherapy toxicity. Asia-Pacific Journal of Clinical Oncology, 7 pp. 281-286.
    [10.1111/j.1743-7563.2011.01409.x] [Scopus]
  • Thanigaimani, S., Kichenadasse, G. and Mangoni, A.A. (2011). The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs. Current Vascular Pharmacology, 9 pp. 358-380.
    [10.2174/157016111795495503] [Scopus]
  • Kichenadasse, G., Nott, L., O'Neill, S., Price, T.J., Karapetis, C.S. and Leung, J.T. (2010). Adjuvant therapy for resected pancreatic adenocarcinoma (Protocol) Cochrane Database of Systematic Reviews, 1 pp. 1-8.
    [10.1002/14651858.CD008336]
  • Karapetis, C.S. and Kichenadasse, G. (2008). Targeted therapies in colorectal cancer. Cancer Forum, 32(3) pp. 150-155.
    [Scopus] [Web Link]
  • Kichenadasse, G., ZAKARIA, J., RODDA, D.J., Hewett, P.J., Rieger, N., STEPHENS, J.H., et al. (2007). Squamous cell carcinoma of the anal canal at The Queen Elizabeth Hospital: A local experience. Asia-Pacific Journal of Clinical Oncology, 169 pp. 214-218.
    [10.1111/j.1743-7563.2007.00115.x] [Scopus]
  • Kumar, L., Raju, G.M.K., Kichenadasse, G., Sukumaran, S., Menon, H., Wadhwa, J., et al. (2003). High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. National Medical Journal of India, 16(1) pp. 16-21.
    [Scopus]
  • Miners, J.O., Chau, N., Rowland, A., Burns, K.W., McKinnon, R.A., Mackenzie, P.I., et al. (2017). Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubunemia. Biochemical Pharmacology, 129 pp. 85-95.
    [10.1016/j.bcp.2017.01.002]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Wiese, M.D., et al. (2017). Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing interindividual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology, 13(1) pp. 31-49.
    [10.1080/17425255.2016.1229303] [Scopus]
  • Van Dyk, M., Miners, J.O., Kichenadasse, G., McKinnon, R.A. and Rowland, A. (2016). A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: a novel platform for optimised KI dosing. Journal of Chromatography B-Analytical Technologies in The Biomedical and Life Sciences, 1033-1034 pp. 17-26.
    [10.1016/j.jchromb.2016.07.046] [10.1016/j.jchromb.2016.07.046] [Scopus]
  • Rowland, A., Karapetis, C.S., Mangoni, A.A., Wiese, M., Kichenadasse, G., McKinnon, R.A., et al. (2016). Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. Translational Cancer Research, 5(Suppl 1) pp. S31-S34.
    [10.21037/tcr.2016.05.19] [10.21037/tcr.2016.05.19]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Weise, M.D., et al. (2016). Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology,
    [10.1080/17425255.2016.1229303] [10.1080/17425255.2016.1229303]
  • Rowland, A., Van Dyk, M., Mangoni, A.A., Miners, J.O., McKinnon, R.A., Wiese, M., et al. (2016). Kinase inhibitor pharmacokinetics: Comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism and Toxicology,
    [10.1080/17425255.2016.1229303] [10.1080/17425255.2016.1229303]
  • Sorich, M., Kichenadasse, G., Rowland, A., Woodman, R.J. and Mangoni, A.A. (2016). Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF targeted therapy: A pooled secondary analysis of clinical trials. International Journal of Cancer, 138 pp. 2293-2299.
    [10.1002/ijc.29972] [Scopus]
  • Kichenadasse, G., Sweet, L.P., Harrington, A.C. and Ullah, S. (2016). The current practice, preparedness and educational preparation of oncology professionals to provide spiritual care. Asia-Pacific Journal of Clinical Oncology,
    [10.1111/ajco.12654] [10.1111/ajco.12654]
  • Khasraw, M., Lee, A., McCowatt, S., Kerestes, Z., Buyse, M.E., Back, M., et al. (2016). Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. JOURNAL OF NEURO-ONCOLOGY,
    [10.1007/s11060-016-2094-0] [Scopus] [Scopus]
  • Miller, M.D., Zrim, S.A., Lawn, S.J., Woodman, R.J., Leggett, S.M., Jones, L., et al. (2016). A pilot study of self-management-based nutrition and physical activity intervention in cancer survivors. Nutrition and Cancer-An International Journal,
    [10.1080/01635581.2016.1170169] [10.1080/01635581.2016.1170169]

Professional and community engagement

Member, South Australian Medicines Evaluation Panel (SAMEP)

Expertise for media contact

Subject Titles

  • Oncology

Contact

Add to address book
Phone: +61 8 82048997
Email:
Location: Flinders Medical Centre
Postal address: GPO Box 2100, Adelaide 5001, South Australia
MACO login

inspiring achievement